Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find ...

Factorial Inc. (“Factorial”), a leader in solid-state battery technology, today announced that, upon the closing of the ...

Cartesian Therapeutics, Inc. (RNAC) shares ended the last trading session 10.3% higher at $7.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...